ReviewExperimental and therapeutic medicine2019
Immunologic adverse reactions of β-blockers and the skin.
Review in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 48 citations in OpenAlex.
- Persistent Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Metoprolol: Resolution via Beta-blocker Switch.Acta dermato-venereologica · 2026Article
- Cutaneous effects of antihypertensive drugs: A comprehensive narrative review of side effects, management, and prevention.Journal of family medicine and primary care · 2026Review
- Effects of probiotics on blood lipids, glucose and pressure in patients with coronary heart disease: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Psoriasiform rash possibly induced by oral propranolol in a 12-month-old girl with infantile hemangioma: a case report and literature review.Dermatology reports · 2025Article
- Arrhythmias in Rheumatoid Arthritis: A Call for a Multidisciplinary Team.Life (Basel, Switzerland) · 2025Review
- Acrocyanosis: The Least Known Acrosyndrome Revisited With a Dermatologic Perspective.Dermatology research and practice · 2025Review
- Nutritional support contributes to improving cardiac function and nutritional status in atrial fibrillation patients receiving treatment with esmolol hydrochloride.Frontiers in cardiovascular medicine · 2025Article
- The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives.Drug design, development and therapy · 2025Review
- Marfan syndrome: insights from animal models.Frontiers in genetics · 2024Review
- Infantile Hemangioma: A Cross-Sectional Observational Study.Life (Basel, Switzerland) · 2023Article
- Medicinal Treatment of Elderly Psoriasis Patients before and after Entering a Nursing Home.Healthcare (Basel, Switzerland) · 2022Article
- Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review).Experimental and therapeutic medicine · 2022Review
- Benefits and adverse events of melatonin use in the elderly (Review).Experimental and therapeutic medicine · 2022Review
- Clinicopathological correlation of transient acantholytic dermatosis: A case report.Experimental and therapeutic medicine · 2022Article
- Nasopharyngeal carcinoma: A new synthesis of literature data (Review).Experimental and therapeutic medicine · 2022Review
- Defining a Role for G-Protein Coupled Receptor/cAMP/CRE-Binding Protein Signaling in Hair Follicle Stem Cell Activation.The Journal of investigative dermatology · 2022Article
- Clinical, Dermoscopic and Microscopic Features of a "Collision Tumour" Ultimately Confirmed as a Regressing Melanoma - Lessons Learnt from a Chance Diagnosis.Clinical, cosmetic and investigational dermatology · 2022Article
- Cutaneous Eruptions in the Course of COVID-19 Among Geriatric Patients in a Nursing Home in Poland.Clinical, cosmetic and investigational dermatology · 2022Article
- Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report.Experimental and therapeutic medicine · 2022Article
- Rare case of metachronous tumor: Nasopharyngeal and colorectal carcinoma.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently, pemphigus. Since β-blockers are deployed in a variety of disorders, which have cutaneous co-morbidities such as psoriasis, their pertinence to dermatologists cannot be overstated. Likewise, β-blockers, like any other drug category, carry risks of side effects, some of which are dermatologic. These include triggering and exacerbation of psoriasis, psoriatic and rheumatoid arthritis, anaphylaxis, contact dermatitis, occupational contact dermatitis, Raynaud's disease, alopecia, lichen planus-like drug eruption, hyperhydrosis and vitiligo. While recent articles have focussed on the positive uses of β-blockers, it may also be wise to call our attention to the potential dermatologic adverse effects that may follow β-blocker use, as well as possible therapeutic approaches to these. This short review will focus on those dermatoses resulting from β-blocker use, which have an immunologic basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.